Table 6. Cytotoxic Activity (IC50, μM) of the Studied Compounds Estimated by the MTT Assaya.
| PC3d | HaCaTe | ||
|---|---|---|---|
| IC50b | SIc | IC50 | |
| 1 | 68.7 ± 3.4 | 1.4 | 100.4 ± 1.2 |
| 2 | 85.2 ± 8.2 | 0.9 | 75.7 ± 7.5 |
| 3 | 2.02 ± 0.1 | 17.6 | 35.7 ± 8.2 |
| 4 | 51.6 ± 8.1 | 1.9 | >100 |
| 5 | 97.2 ± 11.0 | 1.0 | >100 |
| 6 | 107.9 ± 11.0 | 0.1 | 19.7 ± 2.8 |
| 7 | >100 | 1 | >100 |
| 8 | 39.6 ± 4.3 | 1.1 | 44.9 ± 9.0 |
| 9 | 69.1 ± 5.8 | 1.4 | >100 |
| 10 | 84.1 ± 7.3 | 1.1 | 89.1 ± 2.1 |
| 11 | 81.7 ± 8.9 | 0.9 | 80.1 ± 8.1 |
| 12 | 29.7 ± 5.0 | 1.3 | >100 |
| 13 | 33.7 ± 8.2 | 2.7 | 93.4 ± 10.1 |
| 14 | 63.4 ± 5.3 | 1.6 | >100 |
| 15 | 15.7 ± 3.8 | 5.4 | 85.5 ± 9.2 |
| 16 | 68.8 ± 9.9 | 1.5 | >100 |
| 17 | 88.4 ± 10.6 | 0.5 | 41.3 ± 5.2 |
| 18 | >100 | 0.9 | 92.2 ± 8.7 |
| 19 | 71.4 ± 3.2 | 1.0 | 72.9 ± 5.7 |
| 20 | 69.9 ± 7.2 | 1.3 | 89.5 ± 5.9 |
| 21 | 4.8 ± 0.1 | 15.2 | 73.2 ± 10.1 |
| CP | 100.4 ± 3.6 | 2.2 | 222.1 ± 3.6 |
| doxorubicin | 0.3 ± 0.12 | 1.0 | 0.3 ± 0.11 |
| cisplatin | 13.2 ± 2.10 | 0.5 | 6.3 ± 0.70 |
a
Data are expressed as mean SD.
b
IC50 (μM)—the concentration of the compound that corresponds to a 50% growth inhibition of the cell line (as compared to the control) after 72 h of incubation with the individual compound.
c
The SI (selectivity index) was calculated using the formula SI = IC50 for normal cell line/IC50 cancer cell line.
d
Human metastatic prostate cancer (PC3).
e
Human immortal keratinocyte cell line from adult human skin (HaCaT).